
February 25, 2021
COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
February 25, 2021
A Standing Main Member of ECOG-ACRIN since 2007